Kapila Ratnam Named One Of GrowthCap's Top Healthcare Investors of 2026

NewSpring General Partner Dr. Kapila Ratnam has been named to GrowthCap's Top Healthcare Investors of 2026 list. This annual recognition highlights the most accomplished and trusted investors guiding healthcare companies through today's evolving landscape. GrowthCap evaluates nominees on the strength of their track records, ability to scale companies, investment outcomes, and the support they receive from peers, portfolio executives, and the broader healthcare ecosystem. Kapila's selection reflects her rare combination of deep scientific training, operating experience, and long-tenured investing leadership, and her consistent track record of building and scaling platform businesses across healthcare services, life sciences, and pharmaceutical services.

"This recognition is a testament to the remarkable founders and teams we partner with and to the relationships that define NewSpring. We focus on building deep and enduring partnerships with entrepreneurs, working alongside them to create measurable value as their businesses scale. In healthcare especially, we're inspired by the opportunity to support companies that are advancing care delivery and improving outcomes for patients. I'm proud of what our team has accomplished together and excited to continue partnering with founders who are shaping the future of healthcare." - NewSpring General Partner, Dr. Kapila Ratnam

Dr. Kapila Ratnam is a General Partner at NewSpring, focused on the firm's dedicated healthcare strategy. Since joining NewSpring in 2007, she has brought over two decades of healthcare industry experience to bear on investments across healthcare services, pharmaceutical services, and life sciences, partnering with founders and management teams to accelerate growth, professionalize operations, and drive successful outcomes.

Kapila is known for her ability to underwrite and partner with management teams at the intersection of clinical complexity and scalable business models. Her background in pharmaceutical R&D and healthcare strategy enables her to assess risk, regulatory nuance, and operational execution in a way that few growth equity investors can. She is an active board member and long-term partner to portfolio companies, with board experience spanning provider platforms, healthcare services, and biologics manufacturing. Notable investments include Paragon Bioservices, which grew from a small biologics manufacturer into a scaled CDMO before being acquired for approximately $1.2 billion, as well as AeroSafe Global, vybe urgent care, InHome Therapy, and Patheous Health, among others. Beyond her investing work, Kapila is an active advocate for strengthening women's presence in private equity, mentoring talent and helping shape a more inclusive industry.

Prior to NewSpring, Kapila worked in the health sciences division at PSI International, supporting outsourced services to the pharmaceutical industry and government health service agencies. Before that, she served as a strategy consultant to early-stage pharmaceutical services and biotech companies and worked in R&D at GlaxoSmithKline Pharmaceuticals.

Kapila holds an MBA from Columbia University and a Ph.D. from The Ohio State University.

The GrowthCap Top Healthcare Investor award is prepared by GrowthCap Advisory. The designation is awarded on an annual basis, and Kapila Ratnam received the award in 2026. The list of GrowthCap Top Healthcare Investors for 2026 was published on March 25, 2026.

Our evaluation process is informed by nomination submissions, feedback from colleagues, peers, and portfolio company leaders, and supplemented by in-depth research. In particular, we assess each nominee’s investment history, leadership, and the tangible impact they have had on the companies and teams they work with. The full extent of the scope of firms and data included in the related surveys or evaluations is unknown. Following receipt of the award, NewSpring paid a production fee for the publication of the award.